



## REGENXBIO to Host Webcast Discussing Interim Functional Data from the Phase I/II AFFINITY DUCHENNE® Trial of RGX-202

June 02, 2025 07:05 AM EDT

- *Event will feature Aravindhan Veerapandiyan, M.D., principal investigator of the AFFINITY DUCHENNE® trial*

ROCKVILLE, Md., June 2, 2025 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will host a webcast to discuss new interim functional data from the Phase I/II AFFINITY DUCHENNE® trial of RGX-202, the company's next-generation investigational gene therapy for the treatment of Duchenne muscular dystrophy. The webcast will feature AFFINITY DUCHENNE principal investigator Aravindhan Veerapandiyan, M.D., Arkansas Children's Hospital.

### Webcast details

**Title:** AFFINITY DUCHENNE® Trial of RGX-202: Phase I/II Interim Functional Data

**Date/Time:** Thursday, June 5, 2025, at 8:00 a.m. EDT

**Access:** The live webcast can be accessed [here](#) and in the Investors section of REGENXBIO's website at [www.regenxbio.com](http://www.regenxbio.com). An archived replay of the webcast will be available for approximately 30 days following the presentation.

### ABOUT REGENXBIO Inc.

REGENXBIO is a biotechnology company on a mission to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the field of AAV gene therapy. REGENXBIO is advancing a late-stage pipeline of one-time treatments for rare and retinal diseases, including RGX-202 for the treatment of Duchenne; clemidsogene lanparvovec (RGX-121) for the treatment of MPS II and RGX-111 for the treatment of MPS I, both in partnership with Nippon Shinyaku; and surabgene lomparvovec (ABBV-RGX-314) for the treatment of wet AMD and diabetic retinopathy, in collaboration with AbbVie. Thousands of patients have been treated with REGENXBIO's AAV platform, including those receiving Novartis' ZOLGENSMA®. REGENXBIO's investigational gene therapies have the potential to change the way healthcare is delivered for millions of people. For more information, please visit [www.REGENXBIO.com](http://www.REGENXBIO.com).

### Contacts:

Dana Cormack  
Corporate Communications  
[dcormack@regenxbio.com](mailto:dcormack@regenxbio.com)

Investors:  
George E. MacDougall  
Investor Relations  
[IR@regenxbio.com](mailto:IR@regenxbio.com)



[View original content to download multimedia:https://www.prnewswire.com/news-releases/regenxbio-to-host-webcast-discussing-interim-functional-data-from-the-phase-iii-affinity-duchenne-trial-of-rgx-202-302470286.html](https://www.prnewswire.com/news-releases/regenxbio-to-host-webcast-discussing-interim-functional-data-from-the-phase-iii-affinity-duchenne-trial-of-rgx-202-302470286.html)

SOURCE REGENXBIO Inc.